Third Circuit under fire over FTC v AbbVie ruling
18-11-2020
FTC’s $448m AbbVie win overturned
02-10-2020
AbbVie and Alphabet company commit $1bn to collaboration
27-06-2018
FTC secures partial win against AbbVie
18-09-2017
hynci / iStockphoto.com
Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission (FTC) $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, Besins Healthcare, FTC, generics, patent, sham litigation
